Karyopharm Therapeutics (NASDAQ: KPTI) revenue
Karyopharm Therapeutics reported revenue of $146.1m for fiscal 2025, 0.6% more than in fiscal 2024 ($145.2m). Since fiscal 2016 its revenue has grown by 94,748.7%, an average growth of 114.2% a year.
Karyopharm Therapeutics's best year of the last 10 was fiscal 2021. The biggest drop was in fiscal 2022, −25.1%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $146.1m | +0.6% | −$90.7m | −62.1% |
| 2024 | $145.2m | −0.5% | −$119.4m | −82.2% |
| 2023 | $146.0m | −7.0% | −$129.5m | −88.7% |
| 2022 | $157.1m | −25.1% | −$142.2m | −90.5% |
| 2021 | $209.8m | +94.1% | −$98.3m | −46.8% |
| 2020 | $108.1m | +164.3% | −$171.9m | −159.0% |
| 2019 | $40.9m | +34.8% | −$189.3m | −462.9% |
| 2018 | $30.3m | +1,790.1% | −$179.9m | −593.0% |
| 2017 | $1.6m | +942.2% | −$130.5m | −8,133.2% |
| 2016 | $0.2m | — | −$110.7m | −71,903.9% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Karyopharm Therapeutics revenue compared with its sector
By revenue for its latest fiscal year, Karyopharm Therapeutics ranks 265th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Karyopharm Therapeutics, 0.6%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 263rd | MacroGenics | $149.5m | −0.3% |
| 264th | Grail | $147.2m | 17.2% |
| 265th | Karyopharm Therapeutics | $146.1m | 0.6% |
| 266th | InfuSystem | $143.4m | 6.4% |
| 267th | Beam Therapeutics | $139.7m | 120.0% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Karyopharm Therapeutics
- How much revenue did Karyopharm Therapeutics make in fiscal 2025?
- Karyopharm Therapeutics reported revenue of $146.1m for fiscal 2025, compared with $145.2m in fiscal 2024.
- How much has the revenue of Karyopharm Therapeutics grown?
- Between fiscal 2016 and fiscal 2025 it went from $0.2m to $146.1m: 94,748.7% more, an average growth of 114.2% a year.
- What was the best year for revenue at Karyopharm Therapeutics?
- Of its last 10 fiscal years, fiscal 2021, with $209.8m.
- Where does Karyopharm Therapeutics rank in its sector by revenue?
- It ranks 265th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Karyopharm Therapeutics come from?
- From the annual report (Form 10-K) that Karyopharm Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Karyopharm Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Karyopharm Therapeutics: the Karyopharm Therapeutics page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.